A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions

Healthy

Interventions

DRUG

Tedizolid Phosphate Oral Formulation 1 (Reference)

Formulation 1 (FM1) powder for oral suspension.

DRUG

Tedizolid Phosphate Oral Formulation 2 (Test)

Formulation 2 (FM2) powder for oral suspension.

Trial Locations (1)

Celerion (Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06609161 - A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) | Biotech Hunter | Biotech Hunter